Progressive Visual Field Loss Despite Controlled IOP
A 62-year-old man with primary open-angle glaucoma has been followed for 5 years. His IOP has ranged 13-16 mmHg on latanoprost nightly and timolol twice daily. Over the past 18 months, serial Humphrey 24-2 fields show a new inferior arcuate defect in the left eye progressing from a mean deviation of -3.2 dB to -7.8 dB, with corresponding retinal nerve fiber layer thinning on OCT. Central corneal thickness is 528 microns. Gonioscopy shows open angles with mild pigment. Optic discs show cupping 0.75 in the right eye and 0.85 in the left, with disc hemorrhage noted in the left eye at the last visit. He denies eye pain, redness, or use of steroids. He asks whether his pressure is 'fine' and why his vision is still getting worse.
1. How do you interpret his 'controlled' IOP in light of the progression, and what does the disc hemorrhage tell you?
Read the worked answer
'Controlled' is a target-relative concept, not an absolute number. An IOP of 13-16 mmHg is normal in a population sense but may be inadequate for this individual eye. Several features argue his target pressure is not being met:
- Progressive structural and functional loss (MD -3.2 to -7.8 dB over 18 months, new arcuate defect, RNFL thinning) is the definition of progression despite the current regimen.
- Thin central cornea (528 microns) means his measured IOP underestimates true pressure relative to average corneas; his actual risk exposure is higher than the number suggests.
- Disc hemorrhage is a strong, independent risk marker for progression and is often seen when IOP is at or near target but the optic nerve head remains vulnerable. Its presence should prompt intensified therapy, not reassurance.
- Rate of change matters: a 4.6 dB decline in 18 months is fast and warrants aggressive action.
So the correct interpretation is: his IOP is not at his individual target, and the disc hemorrhage confirms ongoing active glaucomatous damage.
2. What is your management plan, and how do you decide whether to add medication, use laser, or proceed to surgery?
Read the worked answer
Stepwise intensification with confirmation of adherence and measurement quality first:
- Verify adherence and technique (drops, punctal occlusion, timing) and confirm no steroid exposure or other secondary cause; gonioscopy is open, so angle-closure is excluded.
- Confirm progression with repeat reliable fields and OCT to avoid acting on a single noisy test; the trend here is consistent, so act.
- Lower the target pressure substantially (e.g., aim for a 20-30% further reduction from current levels, targeting low-to-mid single digits to low teens given rapid progression and thin cornea).
Options:
- Add a third agent (e.g., a topical carbonic anhydrase inhibitor or alpha-agonist) as a bridge.
- Selective laser trabeculoplasty is a reasonable adjunct for open-angle glaucoma and can lower IOP and improve adherence burden; consider as an alternative to adding drops.
- Incisive surgery (trabeculectomy or a glaucoma drainage device, or MIGS depending on target and anatomy) should be considered when progression continues despite maximal tolerated medical therapy and laser, especially with a disc hemorrhage and rapid field loss. Given the pace of loss, do not wait for years of failed medical therapy.
Monitoring: repeat fields and OCT in 3-4 months after each change, and document the target pressure explicitly.
3. How would you counsel him about why his vision is worsening despite 'normal' pressure readings?
Read the worked answer
Use plain language and an explicit target-pressure framework:
- Explain that glaucoma damage can continue even when the measured pressure looks average, because the safe pressure for his optic nerve is lower than the population average, and his thin cornea means his true pressure is likely higher than measured.
- Explain the disc hemorrhage as a sign of ongoing optic nerve vulnerability and a reason to treat more aggressively, not a reason to relax.
- Clarify that the goal is to slow or halt further loss, not to restore vision already lost; the field defect present now is permanent, so the priority is protecting remaining vision.
- Emphasize that 'normal' is not the same as 'safe for you', and that his target will be individualized and rechecked.
- Set expectations about treatment burden (drops, possible laser, possible surgery) and the need for regular field and OCT testing to judge success.
- Address adherence and cost/insurance barriers openly, since these are common causes of apparent treatment failure.
Document the discussion and the agreed target pressure in the record.